Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Articles published by BetterLife Pharma Inc.

BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Announces Fully Subscribed Private Placement Financing
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Announces Intent to Complete Private Placement of Units
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Advances BETR-001 IND-enabling Studies
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Announces Extension of Warrants
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Pharma to Host Investors Update Call on September 18, 2023
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Fast Tracks Its US Patent for BETR-001 and Other LSD Derivatives
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Highlights American College of Physicians’ Updated Guidelines for Treating Depression and Announces Closing of Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Continues Progress on BETR-001 IND-Enabling Studies
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife To Present BETR-001 Preclinical Data at the 32nd Annual Meeting of the International Behavioural Neuroscience Society (IBNS) in Niagara Falls, Ontario, Canada
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
Promise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
BetterLife Announces Closing of Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
Tickers BETRF CSE:BETR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.